The historical rank and industry rank for China Resources Pharmaceutical Group's Price-to-Free-Cash-Flow or its related term are showing as below:
HKSE:03320'
s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.16 Med: 5.2 Max: 27.96
Current: 2.83
During the past 11 years, China Resources Pharmaceutical Group's highest Price-to-Free-Cash-Flow Ratio was 27.96. The lowest was 2.16. And the median was 5.20.
HKSE:03320's Price-to-Free-Cash-Flow is ranked better than 95.85% of 506
companies
in the Drug Manufacturers industry
Industry Median: 23.41
vs HKSE:03320: 2.83
During the past 12 months, the average Free Cash Flow per Share Growth Rate of China Resources Pharmaceutical Group was 50.60% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 31.40% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 17.20% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 27.00% per year.
During the past 11 years, China Resources Pharmaceutical Group's highest 3-Year average Free Cash Flow per Share Growth Rate was 40.60% per year. The lowest was 14.00% per year. And the median was 27.95% per year.
China Resources Pharmaceutical Group Price-to-Free-Cash-Flow Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
China Resources Pharmaceutical Group Price-to-Free-Cash-Flow Chart
Competitive Comparison of China Resources Pharmaceutical Group's Price-to-Free-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Pharmaceutical Group's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where China Resources Pharmaceutical Group's Price-to-Free-Cash-Flow falls into.
China Resources Pharmaceutical Group Price-to-Free-Cash-Flow Calculation
China Resources Pharmaceutical Group's Share Price of today is HK$6.19.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$2.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
China Resources Pharmaceutical Group (HKSE:03320) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
China Resources Pharmaceutical Group Price-to-Free-Cash-Flow Related Terms
Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
China Resources Pharmaceutical Group (HKSE:03320) Business Description
CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.
China Resources Pharmaceutical Group (HKSE:03320) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:03320 has been successfully added to your 